Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alnylam Pharmaceuticals is conducting a global observational study titled ‘ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)’. The study aims to describe the epidemiological and clinical characteristics, natural history, and real-world management of ATTR amyloidosis patients. It also seeks to assess the safety and effectiveness of patisiran and vutrisiran in routine clinical practice, and to observe disease progression in pre-symptomatic carriers of a TTR variant.
The interventions being tested are patisiran and vutrisiran, both of which are designed to treat ATTR amyloidosis by targeting the transthyretin protein to reduce amyloid deposits in tissues.
This observational study follows a cohort model and is prospective in nature. It includes patients diagnosed with hereditary or wild-type ATTR amyloidosis, as well as pre-symptomatic carriers of a TTR variant, all of whom will receive routine clinical care.
The study began on September 18, 2020, with the latest update submitted on August 25, 2025. These dates are crucial as they indicate the study’s progress and ongoing data collection efforts.
The outcome of this study could significantly impact Alnylam Pharmaceuticals’ stock performance by providing real-world evidence of the effectiveness of their treatments, potentially boosting investor confidence. In the competitive landscape of amyloidosis treatments, these findings could position Alnylam favorably against its rivals.
The study is currently recruiting, with further details available on the ClinicalTrials portal.